Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
1720.00
-2.90(-0.99%)
At close: 4:00 PM EDT
1720.00
-2.90(-0.99%)
Day’s Range― - ―
52-Week Range1,126.50 - 2,834.50
Previous CloseN/A
Volume119.26K
Average Volume (3M)50.50K
Market Cap
₪196.88M
Enterprise Value309.28
Total Cash (Recent Filing)₪46.67M
Total Debt (Recent Filing)₪183.01M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding11,845,711
10 Day Avg. Volume56,256
30 Day Avg. Volume50,500
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe return to revenue growth indicates recovering demand and improving commercial traction across InterCure’s medical cannabis portfolio, distribution network and dispensing channels. Sustaining this trend could improve operating leverage over time.
Positive Free Cash FlowPositive operating and free cash flow show that the business generated cash after investment during 2025. If maintained, this can support operations, reduce funding dependence and provide flexibility while profitability is rebuilt.
Manageable LeverageLower leverage and a sizable, relatively stable equity base provide some financial resilience. This balance-sheet position may help InterCure absorb continued sector volatility and fund its vertically integrated operating model.
Bears Say
Persistent Net LossesInterCure has not yet converted revenue recovery into sustainable profitability. Continued net losses limit internally generated capital, increase execution risk and leave the business more exposed if demand or product margins weaken.
Margin CompressionA structurally lower gross margin can reduce the earnings benefit of revenue growth and weaken the economics of cultivation, manufacturing and distribution. Restoring margin quality is important for durable operating leverage and cash generation.
Volatile Cash GenerationThe sharp swing from substantial prior-year cash outflows to positive 2025 free cash flow makes the improvement less proven. Persistent volatility could constrain investment planning and create funding needs if cash performance reverses.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 1126.50 and its highest was 2834.50 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪196.88M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is May 06, 2027 which is in 241 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -314.2 earnings per share for the quarter.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 11,845,711 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -314.2 in its last earnings report. Following the earnings report the stock price went up 1.101%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.